Literature DB >> 19740350

Mesangial cell complement receptor 1-related protein y limits complement-dependent neutrophil accumulation in immune complex glomerulonephritis.

Lihua Bao1, Ying Wang, Peili Chen, Menaka Sarav, Mark Haas, Andrew W Minto, Miglena Petkova, Richard J Quigg.   

Abstract

The absence of complement receptor 1 (CR1) related gene/protein y (Crry) leads to embryonic lethality as a result of unrestricted complement activation and concomitant neutrophil infiltration. Here we used Crry(-/-)C3(+/-) mice to investigate the role of Crry in the pathogenesis of immune complex glomerulonephritis (GN). After 3 weeks of immunization with horse spleen apoferritin, six of nine Crry(-/-) C3(+/-) mice and none of the six control C3(+/-) mice developed proliferative GN (P = 0.010). After 5 weeks of immunization, GN scores in Crry(-/-) C3(+/-) mice were 0.67 +/- 0.22 mean +/- standard error of the mean (SEM), compared with 0.32 +/- 0.16 in C3(+/-) mice. Glomerular hypercellularity was attributable to neutrophil infiltration in mice with GN (1.7 +/- 0.3/glomerulus) compared with those without GN (0.4 +/- 0.1/glomerulus) (P = 0.001). Absent staining for alpha-smooth muscle actin and proliferating cell nuclear antigen suggested that mesangial cell proliferation did not play a significant role in this model. Serum C3 levels in Crry(-/-) C3(+/-) mice were approximately 20% and 30% those of wild-type mice and C3(+/-) mice, respectively. To determine whether this acquired hypocomplementaemia was relevant to this GN model system, Crry(-/-) C3(+/-) mouse kidneys were transplanted into wild-type mice followed by immunization with apoferritin for 1 or 2 weeks. Surprisingly, none of the Crry(-/-) C3(+/-) mouse kidneys developed GN at these early time-points, indicating that increasing circulating C3 levels several-fold did not increase susceptibility to GN. Renal expression of decay-accelerating factor was not different among any of the groups studied. Thus, our data indicate that mesangial cell Crry limits complement activation and subsequent neutrophil recruitment in the setting of local immune complex deposition.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19740350      PMCID: PMC2753953          DOI: 10.1111/j.1365-2567.2009.03102.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  45 in total

1.  A critical role for murine complement regulator crry in fetomaternal tolerance.

Authors:  C Xu; D Mao; V M Holers; B Palanca; A M Cheng; H Molina
Journal:  Science       Date:  2000-01-21       Impact factor: 47.728

2.  Tissue distribution of products of the mouse decay-accelerating factor (DAF) genes. Exploitation of a Daf1 knock-out mouse and site-specific monoclonal antibodies.

Authors:  F Lin; Y Fukuoka; A Spicer; R Ohta; N Okada; C L Harris; S N Emancipator; M E Medof
Journal:  Immunology       Date:  2001-10       Impact factor: 7.397

3.  Chemokine and chemokine receptor expression during initiation and resolution of immune complex glomerulonephritis.

Authors:  Hans-Joachim Anders; Volker Vielhauer; Matthias Kretzler; Clemens D Cohen; Stephan Segerer; Bruno Luckow; Lars Weller; Hermann-Josef Gröne; Detlef Schlöndorff
Journal:  J Am Soc Nephrol       Date:  2001-05       Impact factor: 10.121

4.  Decay-accelerating factor expression in the rat kidney is restricted to the apical surface of podocytes.

Authors:  Lihua Bao; O Brad Spiller; Patricia L St John; Mark Haas; Bradley K Hack; Guohui Ren; Patrick N Cunningham; Mona Doshi; Dale R Abrahamson; B Paul Morgan; Richard J Quigg
Journal:  Kidney Int       Date:  2002-12       Impact factor: 10.612

5.  Transgenic expression of a soluble complement inhibitor protects against renal disease and promotes survival in MRL/lpr mice.

Authors:  Lihua Bao; Mark Haas; Susan A Boackle; Damian M Kraus; Patrick N Cunningham; Pierce Park; Jessy J Alexander; Randall K Anderson; Kristin Culhane; V Michael Holers; Richard J Quigg
Journal:  J Immunol       Date:  2002-04-01       Impact factor: 5.422

6.  Administration of a soluble recombinant complement C3 inhibitor protects against renal disease in MRL/lpr mice.

Authors:  Lihua Bao; Mark Haas; Damian M Kraus; Bradley K Hack; Jonathan K Rakstang; V Michael Holers; Richard J Quigg
Journal:  J Am Soc Nephrol       Date:  2003-03       Impact factor: 10.121

7.  Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H.

Authors:  Matthew C Pickering; H Terence Cook; Joanna Warren; Anne E Bygrave; Jill Moss; Mark J Walport; Marina Botto
Journal:  Nat Genet       Date:  2002-07-01       Impact factor: 38.330

8.  Antiarthritic activity of an orally active C5a receptor antagonist against antigen-induced monarticular arthritis in the rat.

Authors:  Trent M Woodruff; Anna J Strachan; Nathan Dryburgh; Ian A Shiels; Robert C Reid; David P Fairlie; Stephen M Taylor
Journal:  Arthritis Rheum       Date:  2002-09

9.  Crry deficiency in complement sufficient mice: C3 consumption occurs without associated renal injury.

Authors:  Marieta M Ruseva; Timothy R Hughes; Rossen M Donev; Baalasubramanian Sivasankar; Matthew C Pickering; Xiaobo Wu; Claire L Harris; B Paul Morgan
Journal:  Mol Immunol       Date:  2008-10-22       Impact factor: 4.407

Review 10.  Chemokines and chemokine receptors are involved in the resolution or progression of renal disease.

Authors:  Hans-Joachim Anders; Volker Vielhauer; Detlef Schlöndorff
Journal:  Kidney Int       Date:  2003-02       Impact factor: 10.612

View more
  2 in total

1.  Complement factor H deficiency accelerates development of lupus nephritis.

Authors:  Lihua Bao; Mark Haas; Richard J Quigg
Journal:  J Am Soc Nephrol       Date:  2010-12-09       Impact factor: 10.121

Review 2.  Complement regulation in renal disease models.

Authors:  Abhijit Naik; Shweta Sharma; Richard J Quigg
Journal:  Semin Nephrol       Date:  2013-11       Impact factor: 5.299

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.